Summary

More potent antiplatelet therapy with prasugrel reduced the rate of ischemic events compared with clopidogrel among patients with acute coronary syndromes with planned percutaneous coronary intervention (PCI). The TRITON-TIMI 38 Trial showed that patients treated with the novel thienopyridine prasugrel had a significant net clinical benefit compared with clopidogrel, the standard therapy for patients undergoing PCI.